Preview Mode Links will not work in preview mode


Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in digital health and the changing dynamic between doctors and patients.

Topics on the show include

  • the emergence of precision medicine and breakthroughs in genomics
  • advances in biopharmaceuticals
  • age-related diseases and aging in place
  • using big data from wearables and sensors
  • transparency in the medical marketplace
  • challenges for connected health entrepreneurs

The audience includes researchers, medical professionals, patient advocates, entrepreneurs, patients, caregivers, solution providers, students, journalists, and investors.

Mar 13, 2023

Dr. Paul Lammers, the Chief Executive Officer at Triumvira Immunologics, is developing personalized medicine to treat solid tumors using an autologous approach to arm the patient-derived cells with a vector that identifies and kills individual cancer cells.  At the forefront of the next generation of immune-oncology, Triumvira uses the Cocoon Platform made by Lonza to automate this process in a closed system to grow and harvest the cells. The ultimate goal is to have this technology available at the point of care in regional cancer centers to allow this cell therapy to be used by more cancer patients. 

Paul elaborates, "The challenge with T cell therapy has been can we also use cell therapy to treat solid tumors? And that's where we feel that with our technology, known as TAC, T Cell Antigen Coupler comes in. We truly think we have an opportunity here, so we feel we are developing first-in-class medications based on that new T cell engineer platform, the TAC. We hope to have an opportunity to focus on different types of targets in solid tumors that will address high unmet needs in cancers like gastric cancer and colorectal cancer and pancreatic cancer, and ovarian and endometrial."

"Our first program is in the clinic targeting HER2, which is a well-known target, especially for breast cancer and also gastric cancer. But we're expanding that. In the second half of this year, we're starting a first clinical trial targeting claudin 18.2, which is an exciting new upcoming target in different solid tumors, especially for gastric, pancreatic, and gastroesophageal cancer. Followed then in the next two years by new targets known as GUCY2C, which is a great target for colorectal cancer, and GPC3, a target for primary liver cancer. So it's an exciting time to build a broad and strong pipeline based on that TAC technology platform."

#Triumvira #TCells #TCellTherapy #TAC #Cancer #SolidTumorCancer #CellTherapy #BreastCancer #GastricCancer

Download the transcript here

Trimvira Immunologics